CAJ | 학술논문

目的：探讨米非司酮联合桂枝茯苓胶囊治疗子宫肌瘤的临床效果，并观察、分析其预后，为临床治疗提供依据。方法选择子宫肌瘤患者150例，按照就诊编号随机分为对照组和观察组，两组各75例，对照组患者给予米非司酮治疗；观察组应用米非司酮联合桂枝茯苓胶囊治疗。两组均治疗12周后评估患者临床疗效、不良反应，并检测治疗前后卵泡生成激素（FSH）、雌二醇（E2）水平。结果观察组治愈率为85．33％（64／75），高于对照组的77．33％（58／75），差异有统计学意义（χ2＝10．35，P ＜0．05）；两组不良反应发生率差异无统计学意义（P ＞0．05）；观察组治疗后月经量、经期及瘤体体积大小分别为（47．50±3．85）mL、（4．15±1．22）mm 和（11．26±0．98）cm3，均低于对照组治疗后，两组均低于治疗前，差异有统计学意义（t ＝9．88、10．13、10．22，均 P ＜0．05）；观察组治疗后血清 FSH 和 LH 分别为（32．06±2．75）U ／L 和（31．16±2．13）U ／L，均低于对照组治疗后，两组均高于治疗前，差异均有统计学意义（t ＝9．67，10．04，均 P ＜0．05）。观察组治疗后血清 E2为（51．40±3．34）pmol／L，高于对照组治疗后的（39．32±3．26）pmol／L，两组均高于治疗前，差异有统计学意义（t ＝9．81，P ＜0．05）。结论应用米非司酮联合桂枝茯苓胶囊对育龄期子宫肌瘤患者进行治疗，其临床疗效较好，能够显著改善患者月经状况和性激素的分泌，不良反应差异不显著，值得临床推广应用。
목적：탐토미비사동연합계지복령효낭치료자궁기류적림상효과，병관찰、분석기예후，위림상치료제공의거。방법선택자궁기류환자150례，안조취진편호수궤분위대조조화관찰조，량조각75례，대조조환자급여미비사동치료；관찰조응용미비사동연합계지복령효낭치료。량조균치료12주후평고환자림상료효、불량반응，병검측치료전후란포생성격소（FSH）、자이순（E2）수평。결과관찰조치유솔위85．33％（64／75），고우대조조적77．33％（58／75），차이유통계학의의（χ2＝10．35，P ＜0．05）；량조불량반응발생솔차이무통계학의의（P ＞0．05）；관찰조치료후월경량、경기급류체체적대소분별위（47．50±3．85）mL、（4．15±1．22）mm 화（11．26±0．98）cm3，균저우대조조치료후，량조균저우치료전，차이유통계학의의（t ＝9．88、10．13、10．22，균 P ＜0．05）；관찰조치료후혈청 FSH 화 LH 분별위（32．06±2．75）U ／L 화（31．16±2．13）U ／L，균저우대조조치료후，량조균고우치료전，차이균유통계학의의（t ＝9．67，10．04，균 P ＜0．05）。관찰조치료후혈청 E2위（51．40±3．34）pmol／L，고우대조조치료후적（39．32±3．26）pmol／L，량조균고우치료전，차이유통계학의의（t ＝9．81，P ＜0．05）。결론응용미비사동연합계지복령효낭대육령기자궁기류환자진행치료，기림상료효교호，능구현저개선환자월경상황화성격소적분비，불량반응차이불현저，치득림상추엄응용。
Objective To explore the clinical effect of mifepristone combined with Guizhifuling tuckahoe capsule for the treatment of uterus myoma,and to observe and analyze the prognosis and provide the basis for clinical treatment.Methods 150 uterus myoma patients were selected and randomly divided into the observation group and the control group according to the treatment number,75 cases in each group.The control group was treated with mife-pristone,the observation group was treated with mifepristone combined with Guizhifuling capsule.Treated for 12 weeks and the clinical therapeutic effect and the adverse reaction were evaluated.The follicle stimulating hormone (FSH), estradiol (E2 )levels before and after treatment were detected.Results The cure rate of the observation group was 85.33% (64 /75),which was higher than that of the control group 77.33% (58 /75),the difference was statistically significant (χ2 =10.35,P <0.05).The incidence rate of adverse reaction between the two groups had no statistically significant difference (P >0.05).The menstruation,menstrual volume and tumor size of the observation group after treatment were (47.50 ±3.85)mL,(4.15 ±1.22)mm and (11.26 ±0.98)cm3 respectively,which were lower than the control group after treatment,two groups were lower than that before treatment,the differences were statistically significant (t =9.88,10.13,10.22,all P <0.05).Serum FSH and LH levels of the observation group after treatment were (32.06 ±2.75)U /L and (31.16 ±2.13)U /L,which were lower than the control group after treatment,two groups were lower than that before treatment,the differences were statistically significant (t =9.67,10.04,all P <0.05).Serum E2 of the observation group was (51.40 ±3.34)pmol/L,which was higher than that of the control group (39.32 ±3.26)pmol/L,the two groups were higher than before treatment,the difference was statistically signif-icant (t =9.81,P <0.05).Conclusion Application of mifepristone combined with Guizhifuling capsule for the treatment of uterus myoma patients with child -bearing period has better clinical efficacy and can significantly improve patients menstrual status and sex hormone secretion.The adverse reactions has no significant differences.It is worth of clinical application.